Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.
'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.'
Recent Corporate Highlights
Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance.
Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003.
Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline.
Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows:
U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041.
U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004.
Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics
Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways.
The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include:
In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1
Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2
Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3
President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4
Cybin's Chief Executive Officer Doug Drysdale recently appeared on Fox News and is increasingly sought by media outlets as a trusted commentator. 5
On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows:
Panel Title: The Home Stretch: Pivotal Trials and Preparing for Launch
Date and Time: Thursday, June 19, 2025, at 9:30 a.m. MDT (11:30 a.m. EDT)
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Sources
NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, https://www.youtube.com/watch?v=KEQFKBME668 (accessed June 9, 2025).
Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, https://www.politico.com/newsletters/future-pulse/2025/05/28/a-psychedelics-hire-at-hhs-00371416 (accessed June 9 2025).
The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, https://www.wsj.com/politics/policy/republican-psychedelic-drug-therapy-fc313ea2 (accessed June 9 2025).
The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, https://apnews.com/article/means-trump-surgeon-general-mushrooms-psychedelic-drugs-72c22ed077409b4bb865214e7ef304a8 (accessed June 9 2025).
Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. https://www.foxnews.com/video/6373914669112
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Visa Stock Plunges: Here's Why This Analyst Is Bullish
Visa (NYSE:V) was amongst several payment processor stocks taking a hit in Friday's trading as crypto's ongoing march toward mainstream adoption has sparked concerns about the implications for the group. Confident Investing Starts Here: Specifically, the Wall Street Journal reported that major retailers are seriously looking into using stablecoins as a way to sidestep the high fees tied to traditional card payments. Companies like Walmart and Amazon have apparently explored creating their own U.S.-based stablecoins, a shift that could potentially save them billions in processing costs by moving away from the conventional banking and card network infrastructure. If either Walmart or Amazon were to launch such a payment system, it could pose a major threat to traditional financial institutions, especially regional and community banks. These retailers not only have enormous customer and employee bases, but also access to massive amounts of consumer data and far fewer regulatory hurdles than banks. That combination has long made them powerful, and potentially disruptive, players in the financial space. Stablecoins are digital tokens typically pegged one-to-one with a government-issued currency like the dollar. They're backed by reserves such as cash or U.S. Treasurys and are currently used mainly for storing value or trading other cryptocurrencies. Whether these retail-led stablecoin projects move forward will likely depend on the outcome of the Genius Act, a bill that would lay the groundwork for stablecoin regulation in the U.S. The legislation recently passed a key procedural step but still needs to clear both the Senate and the House. So, credit card use might get switched to crypto, marking a continuation of sorts as Visa's growth has long been powered by people switching from cash to cards, historically accounting for about two-thirds of its volume growth. For Mizuho's Dan Dolev, an analyst who covers both crypto and payment platforms, a big issue he recently mulled revolved around how much 'US cash conversion runway' remains. Dolev's deep dive into different spending categories suggests that Visa's slower-than-expected growth compared to overall U.S. consumer spending since the pandemic isn't necessarily a sign of weakness. Instead, it's mainly because Americans have been spending more in areas that don't typically rely on cards, like rent or healthcare, and less in card-heavy areas like travel or dining. The good news is this trend is beginning to reverse. More importantly, Dolev believes there's still a lot of untapped potential for card adoption in the U.S. While consensus estimates put card penetration at 80 to 90%, the analyst thinks the real figure is closer to 75%. 'This leaves room for another decade of solid top-line growth domestically. Plus, V's performance in Canada & Nordics offers evidence of above-PCE growth, even when card penetration is >90%,' Dolev said. But whether stablecoin adoption changes all that remains to be seen. All told, for now, Dolev rates V shares as Outperform (i.e., Buy), while his $425 price target makes room for 12-month returns of 20%. (To watch Dolev's track record, click here) The rest of the analyst community remains firmly in V's corner too; the stock claims a Strong Buy consensus rating, based on a mix of 24 Buys and 4 Holds. The average price target stands at $388.85, implying shares will climb 10.5% higher in the months ahead. (See Visa stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
5 hours ago
- Yahoo
‘Big Beautiful Bill' could cause thousands of Kansans to lose Medicaid
TOPEKA (KSNT) — Kansas is facing possible Medicaid cuts due to a bill that was recently passed by the U.S House of Representatives. The Republican-backed bill is widely known as the 'Big-Beautiful Bill,' and one Kansas lawmaker believes it could have an impact on tens of thousands of Kansans. The United Methodist Health Ministry Fund released a report on June 11 detailing how much money Kansas might lose out on. The organization estimates that if the bill is passed, Kansas will lose more than $3.7 billion in Medicaid cuts over the next 10 years. Additionally, it's projected that 13,000 Kansans would lose Medicaid coverage. Kansas State University lowering GPA requirements for 2029 students Republican lawmakers believe passage of the bill could curb federal spending. However, Kansas Democrat Representative Suzanne Wikle is urging Capitol Hill to oppose the bill. 'It is really damaging to Kansans and to Kansas not only in terms of what it could do to our healthcare system especially in rural Kansas, but what it could do to the food assistance program in Kansas, families who want to receive the child tax credit,' Wikle said. 'There's just a lot of implications here that harms Kansans across the board, so I really encourage them to oppose the bill and support Kansans.' The report also says, the 'Big-Beautiful Bill' would cut $700 billion dollars from Medicaid nationwide. For more Capitol Bureau news, click here. Keep up with the latest breaking news in northeast Kansas by downloading our mobile app and by signing up for our news email alerts. Sign up for our Storm Track Weather app by clicking here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
'Recession risks alive' as Canada's manufacturing numbers suffer under Trump tariff regime
The dampening effect of Donald Trump's tariffs on manufacturing and wholesale sales in Canada is leading economists to warn that growth forecasts are in jeopardy and, even worse, that the numbers could portend the start of a recession. Manufacturing and wholesale sales, excluding petroleum, dropped 2.8 per cent and 2.3 per cent, respectively, in April from March, according to Statistics Canada data released on Friday. Analysts surveyed by Bloomberg had expected manufacturing sales to drop two per cent and wholesale sales to fall 0.9 per cent. 'Feedback from respondents highlighted the impact of the recent tariffs imposed by the United States on Canada's manufacturing sector,' Statistics Canada said in a press release. Manufacturers said they were experiencing price increases as well as rising costs for raw materials, shipping and labour. One-third said demand for their products had changed. Trump's tariffs include 25 per cent duties on goods that are non-compliant with the Canada-U.S.-Mexico Agreement, 25 per cent on foreign-made vehicles and 50 per cent on steel and aluminum. Economists said the sales data put gross domestic product (GDP) forecasts in the crosshairs. 'The implications for April and second-quarter GDP are squarely negative and recession risks are alive and well,' David Rosenberg, economist and founder of Rosenberg Research & Associates Inc., said in a note. Andrew Grantham, an economist at CIBC Capital Markets, said the data suggests that GDP growth for April will be downgraded from a 'surprisingly positive' first estimate of 0.1 per cent, and could be the prelude for second-quarter growth 'tracking flat.' First-quarter GDP growth came in at 2.2 per cent, well ahead of estimates for 1.7 per cent. On the manufacturing front, petroleum and coal, vehicle sales and primary metals, such as aluminum, contributed the most to April's decline. Excluding petroleum and coal, manufacturing sales fell 1.8 per cent in April from March and are down 2.7 per cent year over year. 'Adding insult to injury was the 6.8 per cent month-over-month contraction in new manufacturing orders,' Rosenberg said. Orders have fallen in two of the past three months, he said, adding that orders for 'big-ticket durable goods' shrivelled 10.5 per cent in April, 'the sharpest slippage in nearly three years.' Rosenberg said this data is 'key because new orders are, after all, a leading indicator and the mother's milk for future demand.' On the wholesale front, sales fell in six of the seven subsections, accounting for 81.6 per cent of the total. Motor vehicles and parts led the decrease in April, falling 6.5 per cent, a U-turn from March, Statistics Canada said. As the tariff war got underway, Ontario and Quebec were singled out as being among the provinces most vulnerable to Trump's tariffs, something the latest manufacturing and wholesale data supported. Ontario manufacturing sales dropped 2.4 per cent in April, or $31 billion, representing the largest dollar decline since March 2024. Quebec's contracted the second-most in dollar-terms, down $17.5 billion, the fourth straight monthly drop. Ontario also recorded the largest decrease in wholesale sales in dollar terms as the sector contracted $910 million — a decrease of 2.1 per cent. Gary Shapiro: The United States and Canada need each other. Let's make up Don't assume further rate cuts from the Bank of Canada, Poloz warns Rosenberg said the data further questions the Bank of Canada's recent decision to hold interest rates for a second consecutive time at 2.75 per cent at its June 4 announcement. 'How the Bank of Canada can just sit on the sidelines as a casual observer is a good question as the disinflationary output gap widens further,' he said. • Email: gmvsuhanic@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
